Horizon Pharma

Sanofi
Biotech

Horizon snaps up Curzion and its ex-Sanofi rare disease drug

Horizon Therapeutics has added to its growing acquisitive pipeline with the buyout of Curzion Pharmaceuticals for just $45 million.
Ben Adams Apr 3, 2020 8:25am
FDA Building

Horizon eye drug wins FDA panel backing in unanimous vote

Dec 13, 2019 4:54pm
city view

Horizon sets up Bay Area R&D, manufacturing site

Nov 22, 2019 10:15am
LA

New phase 3 data paint fuller picture for Horizon's teprotumumab

Apr 26, 2019 2:05pm
Green light

Horizon Pharma's inflammatory eye drug aces phase 3

Feb 28, 2019 11:02am
A nurse holding the hands of an elderly patient

Selecta unveils more data on its gout drug, plans phase 3 study

Jun 15, 2018 7:00am